Routine health care being pushed off to help treat COVID-19 patients
Written By:
Hayley Smith / Los Angeles Times | 7:00 am, Mar. 2, 2021 ×
Many routine women s health appointments are being pushed or rescheduled due to staff shortages and prioritizing COVID-19 patients. Forum file photo
LOS ANGELES – When Stephanie Fajuri, 36, had an abnormal Pap smear a decade ago, her doctor advised her to come in for annual screenings to keep an eye on her health. She was diligent about doing so regularly until she was confronted by a pandemic.
An appointment scheduled last summer was pushed to December, Fajuri said. By the time she finally saw a doctor, she had developed more abnormal cells and had to undergo a procedure to remove them from her cervix.
DGAP-News: Molecular Health and FALCO biosystems team up to provide genetic analysis services using MH Guide/BRCA and MH Guide/Mendel boersennews.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from boersennews.de Daily Mail and Mail on Sunday newspapers.
® for Histiocytosis. Histiocytoses are rare disorders characterized by a buildup of white blood cells called histiocytes, which leads to tissue damage. This group of disorders is diagnosed in a few thousand people every year across the United States. As a result of this low incidence rate, people are often diagnosed late and receive treatment from doctors who have limited or no prior experience with the disease. These new clinical practice guidelines from NCCN provide the latest evidence and expert-consensus for diagnosing and treating the three most-common forms of histiocytosis in adults: Langerhans cell histiocytosis (LCH), Erdheim-Chester disease (ECD), and Rosai-Dorfman disease.
(1)
EUSA Pharma (UK) Limited (
EUSA Pharma ), a global biopharmaceutical company focused on oncology and rare diseases, announced that the National Comprehensive Cancer Network
(NCCN
) for B-Cell Lymphomas to include siltuximab (SYLVANT
) as the preferred primary treatment for patients with human immunodeficiency virus-negative [HIV(-)] and human herpesvirus 8-negative [HHV-8(-)] multicentric Castleman disease (MCD), also known as idiopathic multicentric Castleman disease (iMCD), regardless of histopathologic subtype.
1 Siltuximab is currently approved in more than 40 countries worldwide for the treatment of all histopathologic subtypes of iMCD, a rare, life-threatening and debilitating orphan condition of the lymph nodes and related tissues. 2,3 The update is based on a 2020 publication which demonstrated that there is insufficient evidence to guide treatment based solely on lymph node histopathologic subtype.
PHOENIX â Cancer screenings in the U.S. have plunged since the start of the pandemic almost a year ago, prompting health advocates to increase calls for the public to stop postponing these potentially life-saving procedures.
More than one-third of adults have failed to receive recommended cancer screenings during the pandemic, according to âCancer Wonât Wait and Neither Should You,â a bulletin published by the American Cancer Society and the National Comprehensive Cancer Network.
Fear of getting COVID-19 at screening centers and job losses that have affected insurance coverage are among the factors driving this dangerous trend.
âThe pandemic has really given cancer the advantage, and the balance of risk has shifted significantly,â Jeff Fehlis, executive vice president of the American Cancer Societyâs south region, said in an interview with Cronkite News.